Ezogabine (retigabine)

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released December 30, 2005; last updated March 28, 2018. This article will no longer be updated as GlaxoSmithKline discontinued the drug in 2017.

Historical note and terminology

Ezogabine, a K channel opener used for treatment of partial-onset seizures in adults, was developed by Valeant Pharmaceuticals and GlaxoSmithKline. In 2011, it was approved by the European Medicines Agency under the trade name Trobalt and by the FDA, under the trade name Potiga. The drug is known as "ezogabine" in the United States and "retigabine" elsewhere. In the fall of 2016, GlaxoSmithKline, the manufacturer of Trobalt (retigabine) announced that this drug will be discontinued and will no longer be commercially available after June 2017. This is due to the very limited use of the drug and the continued decline in new patients being prescribed. Healthcare professionals were advised to begin seeking alternative medicines for existing patients as soon as possible and to ensure that all patients are withdrawn at the latest from this medicine by the end of June 2017. There is no approved generic version of Potiga or Trobalt. It is no longer available.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.